Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naive and COVID-19 recovered individuals
C. Camara, D. Lozano-Ojalvo, E. Lopez-Granados, E. Paz-Artal, M. Pion, R. Correa-Rocha, A. Ortiz, M. Lopez-Hoyos, M. Erro Iribarren, J. Portoles, P. Portoles, M. Perez-Olmeda, J. Oteo-Iglesias, C. Berin, E. Guccione, A. Bertoletti, J. Ochando
Abstract
The rapid development and deployment of mRNA-based vaccines against the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) led to the design of accelerated vaccination schedules that have been extremely effective in naive individuals. While a two-dose immunization regimen with the BNT162b2 vaccine has been demonstrated to provide a 95% efficacy in naive individuals, the effects of the second vaccine dose in individuals who have previously recovered from natural SARS-CoV-2 infection has been questioned. Here we characterized SARS-CoV-2 spike-specific humoral and cellular immunity in naive and previously infected individuals during full BNT162b2 vaccination. Our results demonstrate that the second dose increases both the humoral and cellular immunity in naive individuals. On the contrary, the second BNT162b2 vaccine dose results in a reduction of cellular immunity in COVID-19 recovered individuals, which suggests that a second dose, according to the current standard regimen of vaccination, may be not necessary in individuals previously infected with SARS-CoV-2.
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Mucosal and systemic responses to SARS-CoV-2 vaccination in infection naive and experienced individuals
M. M. Sajadi, A. Myers, … A. D. Harris·bioRxiv·Dec 13, 2021
- Antibody and T cell memory immune response after two doses of the BNT162b2 mRNA vaccine in older adults with and without prior SARS-CoV-2 infection
J. Demaret, B. Corroyer-Simovic, … G. Lefevre·bioRxiv·Jul 8, 2021
- Longitudinal cellular and humoral immune responses following Covid-19 BNT162b2-mRNA-based booster vaccination of craft and manual workers in Qatar.
Remy Thomas, Ahmed Zaqout, … Julie V. Decock·Frontiers in ImmunologyPeer-reviewed·Mar 27, 2025
- Temporal associations of B and T cell immunity with robust vaccine responsiveness in a 16-week interval BNT162b2 regimen
M. Nayrac, M. Dube, … D. E. Kaufmann·bioRxiv·Dec 18, 2021
- A long interval between priming and boosting SARS-CoV-2 mRNA vaccine doses enhances B cell responses with limited impact on T cell immunity
A. Nicolas, G. Sannier, … D. E. Kaufmann·bioRxiv·Aug 3, 2022
- Rapid induction of antigen-specific CD4+ T cells guides coordinated humoral and cellular immune responses to SARS-CoV-2 mRNA vaccination
M. M. Painter, D. Mathew, … E. J. Wherry·bioRxiv·Apr 21, 2021